Expanding Market Access Better Therapeutics has recently partnered with the American College of Lifestyle Medicine to expand access to AspyreRx across over 1,400 Federally Qualified Health centers, indicating a strong opportunity to further collaborate with healthcare providers looking to integrate digital therapeutics into primary care settings.

Recent Product Launches The launch of AspyreRx in October 2023 demonstrates the company's active pipeline of prescription digital therapeutics targeting type 2 diabetes, which can be leveraged to present tailored expansion and scaling opportunities within diabetes management programs.

Regulatory Milestones Receiving the FDA Breakthrough Device Designation for their CBT platform targeting metabolic diseases highlights the company's innovative edge and regulatory credibility, positioning it as a preferred partner for healthcare organizations prioritizing cutting-edge digital health solutions.

Strategic Asset Divestment Commercial asset sale to Click Therapeutics in May 2024 suggests potential avenues for joint ventures or licensing agreements, opening the door to collaborative growth with larger players in the digital therapeutics ecosystem.

Technology & Integration Integration with Glooko’s diabetes management platform reveals opportunities to offer seamless digital health solutions to existing diabetes care networks, making it easier for healthcare providers and payers to prescribe and monitor digital therapeutics for their patients.